Less Ads, More Data, More Tools Register for FREE

IP Group reports half year profit

Tue, 21st Aug 2012 07:12
FTSE 250 intellectual property development firm IP Group reported an adjusted half year pre-tax profit versus a loss the previous year as net assets increased.The group, which recently announced the proposed acquisition of Proximagen Group, also said it expects full-year revenues in excess of £8.5m and adjusted EBITDA in excess of £3m.For the half-year ended 30 June 2012 adjusted pre-tax profit came in at £31.2m, excluding a £2.5m reduction in fair value of Oxford Equity Rights asset, compared to a loss of £1.1m in the same half in 2011. Net assets at 30 June 2012 increased to £250.7m from £222.6m a year earlier.In June IP Group announced it would invest in The Marblar platform, an online network for inventors to interact directly with the scientific research community to come up with new ways to exploit scientific discoveries. It is aimed at boosting the chances of turning scientific discoveries into viable products and businesses. Commenting on the half-yearly results, chief executive Alan Aubrey, said: "The group has continued to increase the rate of deployment of the funds raised through its 2011 placing and our balance sheet remains strong with cash resources of £43.2m.""Many of our portfolio companies have announced significant further financings this year, including Oxford Nanopore and the admission to AIM of Retroscreen Virology and Revolymer."IP added that it remains well placed for future trading. CJ Ip Group

Shares in this article

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Corporate News Ip Group + 1 more share